Anvisa aprova uso de Mounjaro para tratamento contra obesidade…
O fármaco já estava autorizado para uso no Brasil desde 2023, mas era indicado em bula apenas para o tratamento do diabetes tipo 2.
O fármaco já estava autorizado para uso no Brasil desde 2023, mas era indicado em bula apenas para o tratamento do diabetes tipo 2.
comunicacao@sincofarma.org.br
Rua Santa Isabel, 160 – 6.º Andar Vila Buarque – São Paulo – SP CEP: 01221-010
Cookie | Duração | Descrição |
---|---|---|
cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |